Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03604861 · ClinicalTrials.gov registry record

An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery

A clinical trial of Opioid Use Disorder and Opioid-Related Disorders, sponsored by Indivior.

Completed
Registry status
534
Enrollment target
20
Study locations

NCT03604861: Completed study of Opioid Use Disorder and Opioid-Related Disorders, sponsored by Indivior.

NCT03604861 is a study of Opioid Use Disorder and Opioid-Related Disorders that has completed, run by Indivior. The registered enrollment target is 534 participants, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03604861, a study of Opioid Use Disorder and Opioid-Related Disorders, has completed, sponsored by Indivior.

COMPLETED
Registry status
534 participants
Enrollment target
20
Study locations

Study Summary

The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine extended-release injection (RBP-6000). The study population will consist of participants from studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003). The RECOVER study will characterize OUD subjects' recovery process as they transition from the controlled clinical trial environment to the real world setting.

Primary Outcome

Based on self-reported abstinence from opioids using the National Survey on Drug Use and Health (NSDUH).

Interventions

  • OTHER Not applicable - no defined intervention

Study Locations (20)

Florida

  • Amit Vijapura - Jacksonville
  • Meridien Research - Lakeland
  • Try Research - Maitland
  • Innovative Clinical Research - Miami
  • Scientific Clinical Research - Miami
  • Research Centers of America - Oakland Park

California

  • Behavioral Research Specialists - Glendale
  • Collaborative Neuroscience Networks, Inc. - Long Beach
  • Synergy Research Center - National City
  • North County Clinical Research - Oceanside
  • Artemis Institute for Clinical Research - San Diego

Alabama

  • Winston Technology Research LLC - Haleyville
  • Boyett Health Services - Hamilton

Louisiana

  • Louisiana Research Associates - New Orleans
  • Louisiana Clinical Research - Shreveport

Massachusetts

  • Stanley Street Treatment and Resources - Fall River
  • Adams Clinical Trials - Watertown

Arkansas

  • Woodland International Research Group - Little Rock

Mississippi

  • Precise Research Centers, Inc. - Flowood

Missouri

  • St. Louis Clinical Trials - St Louis

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2015-08
Est. Completion 2019-03
Indivior

37 total trials

What the finished NCT03604861 record still lists

NCT03604861 is an observational study that tracks outcomes without assigning an intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Not applicable - no defined intervention is the first listed.

NCT03604861 names 20 study sites across 8 states, led by Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT03604861 about?

NCT03604861 is a clinical study titled "An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery". The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine extended-release injection (RBP-6000). The study population will consist of particip...

What is the current status of trial NCT03604861?

This trial is currently completed. The enrollment target is 534 participants. The study started on 2015-08. Estimated completion is 2019-03.

What conditions does trial NCT03604861 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Opioid-Related Disorders.

What interventions are being tested in trial NCT03604861?

The interventions under investigation include: Not applicable - no defined intervention (OTHER).

Who is sponsoring clinical trial NCT03604861?

This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03604861 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03604861's enrollment target sits among peer trials

534 32nd of 257 higher than 226 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • NCT05614739 · 535 participants · Phase 1

    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

  • NCT07091617 · 535 participants · NA

    Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03604861, the US trial registry maintained by the National Library of Medicine. NCT03604861 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.